0000000000666338

AUTHOR

Marina B. Klein

showing 2 related works from this author

Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease

2019

In Press.

Variceal bleedingTransient elastographyBaveno VI criteria; HCV coinfection; esophagogastroduodenoscopy; transient elastography; variceal bleedingesophagogastroduodenoscopyBaveno VI criteriaHCV coinfectionvariceal bleedingEsophagogastroduodenoscopytransient elastography
researchProduct

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabin…

2019

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed vira…

MaleDOLUTEGRAVIRSustained Virologic ResponseHIV InfectionsGastroenterologychemistry.chemical_compound0302 clinical medicineMedicine and Health SciencesEmtricitabine030212 general & internal medicinePharmacology & PharmacyDarunavir0303 health sciencesAlanineDrug SubstitutionCobicistatEmtricitabine Tenofovir Disoproxil Fumarate Drug CombinationLamivudineAntiretroviralsMiddle AgedViral LoadOPEN-LABEL3. Good healthWEIGHT-GAINDrug CombinationsTreatment OutcomeDolutegravirNON-INFERIORITYFemaleSafetyViral loadLife Sciences & Biomedicinemedicine.drugTabletsAdultmedicine.medical_specialtyEfficacyAnti-HIV AgentsRITONAVIREmtricitabineTENOFOVIR ALAFENAMIDELAMIVUDINETenofovir alafenamideSingle-tablet regimen03 medical and health sciencesInternal medicineVirologymedicineVIH (Virus)HumansSwitch studyProtease InhibitorsTenofovirDarunavirAgedPharmacologyScience & Technology030306 microbiologybusiness.industryHIV (Viruses)AdenineDarunavir/cobicistat/emtricitabine/TAFAntiretroviral agentsCOBICISTATMAINTENANCEchemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHIV-1RitonavirCobicistat[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessRESISTANCE
researchProduct